BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21345941)

  • 1. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.
    Katsumata N; Hirai Y; Kamiura S; Sugiyama T; Kokawa K; Hatae M; Nishimura R; Ochiai K
    Ann Oncol; 2011 Jun; 22(6):1353-1357. PubMed ID: 21345941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
    Tanigawa T; Matoda M; Yamamoto A; Nomura H; Okamoto S; Sakamoto K; Kondo E; Omatsu K; Kato K; Takeshima N
    Arch Gynecol Obstet; 2016 Mar; 293(3):633-8. PubMed ID: 26305033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
    Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
    Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
    Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
    Koizumi W; Kurihara M; Nakano S; Hasegawa K
    Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy.
    Mabuchi S; Yokoi E; Shimura K; Komura N; Matsumoto Y; Sawada K; Isobe A; Tsutsui T; Kitada F; Kimura T
    Int J Gynecol Cancer; 2019 Mar; 29(3):474-479. PubMed ID: 30833436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    Aoki Y; Ochiai K; Lim S; Aoki D; Kamiura S; Lin H; Katsumata N; Cha SD; Kim JH; Kim BG; Hirashima Y; Fujiwara K; Kim YT; Kim SM; Chung HH; Chang TC; Kamura T; Takizawa K; Takeuchi M; Kang SB
    Br J Cancer; 2018 Aug; 119(5):530-537. PubMed ID: 30072745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
    Goto A; Yamada Y; Yasui H; Kato K; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Ann Oncol; 2006 Jun; 17(6):968-73. PubMed ID: 16603600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Okamoto K; Otsuji E; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Yamashita T; Taniguchi F; Aragane H; Nishi H; Itokawa Y; Morita S; Sakamoto J
    Gastric Cancer; 2010 Aug; 13(3):149-54. PubMed ID: 20820983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
    Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
    Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
    Nishiyama O; Taniguchi H; Kondoh Y; Takada K; Baba K; Saito H; Sugino Y; Yamamoto M; Ogasawara T; Kondo M; Imaizumi K; Hasegawa Y; Suzuki R; Shimokata K;
    Anticancer Drugs; 2011 Sep; 22(8):811-6. PubMed ID: 21317767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
    Saek T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Aoyama H; Ota J; Noguchi S; Taguchi T
    Breast Cancer; 2004; 11(2):194-202. PubMed ID: 15550867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
    Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
    Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.